Michal Elovitz, MD, discusses new preterm birth data at SMFM

A roundup of the most impactful FDA approvals in women’s health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

As strains of antibiotic-resistant gonorrhea spread, zoliflodacin provides an alternative oral treatment with non-inferiority to other methods.

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

A novel oral antibiotic, gepotidacin (Blujepa; GSK), has demonstrated its effectiveness in treating uncomplicated urogenital gonorrhea, according to the results of a recent phase 3 clinical trial.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.